Genzyme Extends Deadline for Tender Offer to Acquire AnorMED Inc.

Click this link to view company snapshots
Search Blogs that Mention this News Release
Click this link to view linked Bookmarking Services
Click this link to view linked Blogging Services
Genzyme Extends Deadline for Tender Offer to Acquire AnorMED Inc.
    CAMBRIDGE, Mass., Oct. 6 /PRNewswire-FirstCall/ -- Genzyme Corporation
(Nasdaq: GENZ) announced today that it has extended its offer to acquire
the outstanding shares of AnorMED Inc. (Nasdaq: ANOR) of Vancouver, British
Columbia until 12:01 a.m. Vancouver time on October 23, 2006. Prior to this
extension, Genzyme's offer was set to expire at 12:01 a.m. Vancouver time
on October 7.
    Genzyme offered on August 30 to acquire AnorMED's outstanding shares
for US $8.55 per outstanding share, or approximately $380 million. Genzyme
may elect to extend its offer again by giving notice of such extension to
AnorMED shareholders, a copy of which will be filed with the securities
regulatory authorities in Canada and the United States and which should
also be made available by such authorities through the Internet at
http://www.sedar.com or http://www.sec.gov.
    About Genzyme
    One of the world's leading biotechnology companies, Genzyme is
dedicated to making a major positive impact on the lives of people with
serious diseases. This year marks the 25th anniversary of Genzyme's
founding. Since 1981, the company has grown from a small start-up to a
diversified enterprise with more than 8,500 employees in locations spanning
the globe and 2005 revenues of $2.7 billion. Genzyme has been selected by
FORTUNE as one of the "100 Best Companies to Work for" in the United
States.
    With many established products and services helping patients in more
than 80 countries, Genzyme is a leader in the effort to develop and apply
the most advanced technologies in the life sciences. The company's products
and services are focused on rare inherited disorders, kidney disease,
orthopedics, cancer, transplant and immune diseases, and diagnostic
testing. Genzyme's commitment to innovation continues today with a
substantial development program focused on these fields, as well as heart
disease and other areas of unmet medical need.
    Important Information Regarding the Tender Offer
    Investors and security holders are urged to read the disclosure
documents filed with the Securities and Exchange Commission (the "SEC")
from time to time, including the tender offer statement filed on September
1, 2006, regarding the tender offer by Genzyme's wholly owned subsidiary,
Dematal Corp., for all of the outstanding common shares of AnorMED.
Investors and security holders may obtain a free copy of the disclosure
documents and other documents filed by Genzyme or Dematal with the SEC at
the SEC's website at http://www.sec.gov. In addition, documents filed with
the SEC by Genzyme or Dematal may be obtained free of charge from Genzyme
by directing a request to Sally Curley at (617)768-6140.
    Genzyme(R) is a registered trademark of Genzyme Corporation. All rights
reserved.
    Genzyme's press releases and other company information are available at
http://www.genzyme.com and by calling Genzyme's investor information line
at 1-800-905-4369 within the United States or 1-703-797-1866 outside the
United States.
    Media Contact:       Investor Contact:
    Dan Quinn            Sally Curley
    (617) 768-6849       (617) 768-6140
SOURCE Genzyme Corporation
http://www.genzyme.com
http://www.prnewswire.com/comp/113803.html/
CONTACT:
Dan Quinn (Media), +1-617-768-6849, or Sally
Curley (Investor), +1-617-768-6140, both of Genzyme Corporation